tiprankstipranks

ImmunoGen downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Michael Schmidt downgraded ImmunoGen (IMGN) to Neutral from Buy with a price target of $31, up from $25, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on IMGN:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue